Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3209590 versus insulin degludec in type 2 diabetes mellitus
CTR20221574Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jul 2022; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20221574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221574.